| Katherine Davoren, MD | |
|
1076 N Main St, Providence, RI 02904-5760 | |
| (401) 861-7711 | |
| (401) 421-5710 |
| Full Name | Katherine Davoren |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 10 Years |
| Location | 1076 N Main St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356610406 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Nna Of Providence | Providence, RI | Dialysis facility |
| Bio-medical Applications Of Rhode Island | Lincoln, RI | Dialysis facility |
| Nna - Pawtucket | Pawtucket, RI | Dialysis facility |
| The Miriam Hospital | Providence, RI | Hospital |
| Rhode Island Hospital | Providence, RI | Hospital |
| Roger Williams Medical Center | Providence, RI | Hospital |
| Our Lady Of Fatima Hospital | North providence, RI | Hospital |
| Kent County Memorial Hospital | Warwick, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hypertension And Nephrology, Inc. | 4981619558 | 5 |
News Archive
Kaiser Permanente announced today that every medical facility within the health system is now equipped with Kaiser Permanente HealthConnect®, the largest private sector electronic health record in the world.
Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.
According to a new study, the neuron-killing pathology of Alzheimer's disease (AD), which begins before clinical symptoms appear, requires the presence of both amyloid-beta (a-beta) plaque deposits and elevated levels of an altered protein called p-tau.
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer. The protein is immunoglobulin containing proline rich receptor-1 (IGPR-1) which was recently identified in the same laboratory as a cell adhesion molecule.
› Verified 5 days ago
| Entity Name | Hypertension & Nephrology, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639277072 PECOS PAC ID: 4981619558 Enrollment ID: O20060426000799 |
News Archive
Kaiser Permanente announced today that every medical facility within the health system is now equipped with Kaiser Permanente HealthConnect®, the largest private sector electronic health record in the world.
Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.
According to a new study, the neuron-killing pathology of Alzheimer's disease (AD), which begins before clinical symptoms appear, requires the presence of both amyloid-beta (a-beta) plaque deposits and elevated levels of an altered protein called p-tau.
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer. The protein is immunoglobulin containing proline rich receptor-1 (IGPR-1) which was recently identified in the same laboratory as a cell adhesion molecule.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Katherine Davoren, MD 1076 N Main St, Providence, RI 02904-5760 Ph: (401) 861-7711 | Katherine Davoren, MD 1076 N Main St, Providence, RI 02904-5760 Ph: (401) 861-7711 |
News Archive
Kaiser Permanente announced today that every medical facility within the health system is now equipped with Kaiser Permanente HealthConnect®, the largest private sector electronic health record in the world.
Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with multiple standard treatment regimens for patients with advanced HER2 positive (HER2+) solid tumors.
According to a new study, the neuron-killing pathology of Alzheimer's disease (AD), which begins before clinical symptoms appear, requires the presence of both amyloid-beta (a-beta) plaque deposits and elevated levels of an altered protein called p-tau.
Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer. The protein is immunoglobulin containing proline rich receptor-1 (IGPR-1) which was recently identified in the same laboratory as a cell adhesion molecule.
› Verified 5 days ago
Christopher Donald Palmer, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-274-1122 Fax: 401-453-7597 | |
Martha Catherine Trimbur, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 245 Chapman St Ste 300, Providence, RI 02905 Phone: 401-444-4741 Fax: 401-444-4445 | |
Karl Herman, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Fain Bldg., Providence, RI 02906 Phone: 401-793-4489 Fax: 401-793-4047 | |
Muhammad Baig, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Fain Bldg, Providence, RI 02906 Phone: 401-793-4489 Fax: 401-793-4047 | |
Dr. Peter Sidhom, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: 825 Chalkstone Ave, Providence, RI 02908 Phone: 603-560-2276 | |
Dr. Kanhai Farrakhan, MD Nephrology Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-457-3336 Fax: 401-525-2349 | |
Gary M Katzman, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 208 Collyer Street, Suite 100, Providence, RI 02904 Phone: 401-793-7191 Fax: 401-793-7200 |